In cancer-related VTE, DOACs reduce recurrent VTE compared with LMWH; groups do not differ for major bleeding.

In cancer-related VTE, DOACs reduce recurrent VTE compared with LMWH; groups do not differ for major bleeding. Ann Intern Med. 2020 Dec 15;173(12):JC62 Authors: Mahajan A, White RH Abstract SOURCE CITATION: Haykal T, Zayed Y, Deliwala S, et al. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized controlled trials. Thromb Res. 2020;194:57-65. 32788122. PMID: 33316186 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33316186?dopt=Abstract

Source: Annals of Internal Medicine - December 15, 2020 Category: Internal Medicine Authors: Mahajan A, White RH Tags: Ann Intern Med Source Type: research